15
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Sex and Gender in Neurodegenerative Diseases

      Submit here before September 30, 2024

      About Neurodegenerative Diseases: 1.9 Impact Factor I 5.9 CiteScore I 0.648 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Molecular Genetics of Alzheimer Disease: Identification of Genes and Gene Mutations

      review-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Alzheimer disease (AD), the major form of senile dementia, is rapidly becoming a major health problem in developed countries since as populations live longer the number of elderly people continues to grow. Simultaneously, the number of AD cases is increasing since AD is mainly a late-onset disorder and since no effective therapies are available. The primary causes of AD have not yet been elucidated. However, several researchers in different disciplines are actively engaged in AD research with one ultimate goal, i.e. trying to understand the disease pathology. Knowledge of the biochemical basis of the disease may eventually lead to a therapy which either prevents AD or allows AD patients to be treated. One such discipline is molecular genetics. The aim of molecular genetic studies is to identify genes that are either responsible for or contribute to the expression of AD. Once such a gene is identified, studies of its normal and/or abnormal gene product may help us understand the primary disease mechanisms and lead to more effective therapy. Currently, 3 genetic loci have been identified that predispose to AD: AD1 on chromosome 21, AD2 on chromosome 19, and AD3 on chromosome 14. This review aims at summarizing the progresses that have made in identifying genes and gene mutations that predispose to AD.

          Related collections

          Author and article information

          Journal
          ENE
          Eur Neurol
          10.1159/issn.0014-3022
          European Neurology
          S. Karger AG
          0014-3022
          1421-9913
          1995
          1995
          12 February 2008
          : 35
          : 1
          : 8-19
          Affiliations
          Laboratory of Neurogenetics, Born Bunge Foundation, and Department of Biochemistry, University of Antwerp (UIA), Antwerp, Belgium
          Article
          117083 Eur Neurol 1995;35:8–19
          10.1159/000117083
          7737252
          f055f293-0378-4a31-a010-15da1bbe54e0
          © 1995 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          : 12 October 1993
          : 19 March 1994
          Page count
          Pages: 12
          Categories
          Clinical Review

          Geriatric medicine,Neurology,Cardiovascular Medicine,Neurosciences,Clinical Psychology & Psychiatry,Public health
          Alzheimer disease,Amyloid protein precursor,Dementia,Chromosome 19,Chromosome 14,Chromosome 21,Apolipoprotein E

          Comments

          Comment on this article